These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 29891914)
21. Antiphospholipid syndrome: a comprehensive review of a complex and multisystemic disease. Palomo I; Segovia F; Ortega C; Pierangeli S Clin Exp Rheumatol; 2009; 27(4):668-77. PubMed ID: 19772805 [TBL] [Abstract][Full Text] [Related]
22. Intravenous immunoglobulins and antiphospholipid syndrome: How, when and why? A review of the literature. Tenti S; Cheleschi S; Guidelli GM; Galeazzi M; Fioravanti A Autoimmun Rev; 2016 Mar; 15(3):226-35. PubMed ID: 26656906 [TBL] [Abstract][Full Text] [Related]
23. Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Lopez LR; Dier KJ; Lopez D; Merrill JT; Fink CA Am J Clin Pathol; 2004 Jan; 121(1):142-9. PubMed ID: 14750252 [TBL] [Abstract][Full Text] [Related]
24. Antiphospholipid antibodies. A marker for thrombosis and recurrent abortion. Khamashta MA; Hughes GR Clin Rev Allergy; 1994; 12(3):287-96. PubMed ID: 7804960 [No Abstract] [Full Text] [Related]
25. Quantitative abnormalities of peripheral blood distinct T, B, and natural killer cell subsets and clinical findings in obstetric antiphospholipid syndrome. Carbone J; Gallego A; Lanio N; Navarro J; Orera M; Aguaron A; Fernandez-Cruz E; Sarmiento E J Rheumatol; 2009 Jun; 36(6):1217-25. PubMed ID: 19332638 [TBL] [Abstract][Full Text] [Related]
26. Diagnosis and management of the antiphospholipid syndrome. Chaturvedi S; McCrae KR Blood Rev; 2017 Nov; 31(6):406-417. PubMed ID: 28784423 [TBL] [Abstract][Full Text] [Related]
28. [Significance of the determination of B2-glycoprotein-1 antibodies in recognizing the thrombogenicity in antiphospholipid syndrome]. Serdiuk GV; Selivanov EV; Barkagan ZS Klin Lab Diagn; 2008 Mar; (3):38-9. PubMed ID: 18453060 [TBL] [Abstract][Full Text] [Related]
29. Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements. Žigon P; Podovšovnik A; Ambrožič A; Tomšič M; Hočevar A; Gašperšič N; Rotar Ž; Praprotnik S; Šemrl SS; Čučnik S Clin Rheumatol; 2019 Feb; 38(2):371-378. PubMed ID: 30099654 [TBL] [Abstract][Full Text] [Related]
30. Antiphosphatidylethanolamine antibodies and the antiphospholipid syndrome. Sanmarco M; Boffa MC Lupus; 2009 Sep; 18(10):920-3. PubMed ID: 19671793 [TBL] [Abstract][Full Text] [Related]
31. Antiphospholipid syndrome pathogenesis in 2023: an update of new mechanisms or just a reconsideration of the old ones? Raschi E; Borghi MO; Tedesco F; Meroni PL Rheumatology (Oxford); 2024 Feb; 63(SI):SI4-SI13. PubMed ID: 38320591 [TBL] [Abstract][Full Text] [Related]
32. The role of TLR4 in pathophysiology of antiphospholipid syndrome-associated thrombosis and pregnancy morbidity. Xie H; Sheng L; Zhou H; Yan J Br J Haematol; 2014 Jan; 164(2):165-76. PubMed ID: 24180619 [TBL] [Abstract][Full Text] [Related]
33. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. Danowski A; de Azevedo MN; de Souza Papi JA; Petri M J Rheumatol; 2009 Jun; 36(6):1195-9. PubMed ID: 19447935 [TBL] [Abstract][Full Text] [Related]
34. Risk assessment in patients with antiphospholipid antibodies. Bertero M; Kuzenko A Minerva Med; 2013 Dec; 104(6):639-48. PubMed ID: 24316917 [TBL] [Abstract][Full Text] [Related]
35. Clinical relevance of nitrated beta 2-glycoprotein I in antiphospholipid syndrome: Implications for thrombosis risk. Krilis M; Qi M; Ioannou Y; Zhang JY; Ahmadi Z; Wong JWH; Vlachoyiannopoulos PG; Moutsopoulos HM; Koike T; Sturgess AD; Chong BH; Krilis SA; Giannakopoulos B J Autoimmun; 2021 Aug; 122():102675. PubMed ID: 34098405 [TBL] [Abstract][Full Text] [Related]
36. Anti-beta-2 glycoprotein I epitope specificity: from experimental models to diagnostic tools. Meroni PL Lupus; 2016 Jul; 25(8):905-10. PubMed ID: 27252268 [TBL] [Abstract][Full Text] [Related]
37. Recurrent miscarriages in women not fulfilling classification criteria for antiphospholipid antibody syndrome. Proietta M; Ferrero S; Ferri L; Cifani N; Bruno G; Del Porto F Int J Immunopathol Pharmacol; 2014; 27(3):429-32. PubMed ID: 25280034 [TBL] [Abstract][Full Text] [Related]
38. Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment. Asherson RA; Cervera R; Merrill JT; Erkan D Semin Thromb Hemost; 2008 Apr; 34(3):256-66. PubMed ID: 18720305 [TBL] [Abstract][Full Text] [Related]
39. Role of tissue factor in the maternal immunological attack of the embryo in the antiphospholipid syndrome. Girardi G Clin Rev Allergy Immunol; 2010 Dec; 39(3):160-5. PubMed ID: 19921475 [TBL] [Abstract][Full Text] [Related]
40. Antiphospholipid syndrome: long-time research on pathogenic mechanisms has finally lead to new therapeutic strategies. Cervera R; Espinosa G Expert Opin Ther Targets; 2010 Dec; 14(12):1279-82. PubMed ID: 21058919 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]